The Lancet Respiratory Medicine, 9(6), 573-584. Elsevier Limited Hoeper, M M, Al-Hiti, H, Benza, R L, Chang, S-A, Corris, P A, Gibbs, J S R, Grünig, E, Jansa, P, Klinger, J R, Langleben, D, McLaughlin, V V, Meyer, G M B, Ota-Arakaki, J, Peacock, A J, Pulido, T, Rosenkranz, S, Vizza, C D, Vonk-Noordegraaf, A, White, R J, Chang, M, Kleinjung, F, Meier, C, Paraschin, K, Ghofrani, H A, Simonneau, G & The REPLACE investigators 2021, ' Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE) : a multicentre, open-label, randomised controlled trial ', The Lancet Respiratory Medicine, vol. 9, no. 6, pp. 573-584 . https://doi.org/10.1016/S2213-2600(20)30532-4 REPLACE investigators 2021, ' Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial ', The Lancet Respiratory Medicine, vol. 9, no. 6, pp. 573-584 . https://doi.org/10.1016/S2213-2600(20)30532-4